药物代谢和药物相互作用体外研究试剂
Product Summary
|
|
1) CYPxxxR Bactosomes (human) 人细胞色素cytochrome P450 (CYP)
|
|
Human CYP co-expressed with human NADPH-CYP reductase in E. coli
|
|
Enzyme
|
Product Description
|
CYP1A1
|
CYP1A1R Bactosomes
|
CYP1A1LR Bactosomes
|
|
CYP1A2
|
CYP1A2R Bactosomes
|
CYP1A2LR Bactosomes
|
|
CYP1B1.1
|
CYP1B1LR Bactosomes
|
CYP1B1.3
|
CYP1B1*3LR Bactosomes
|
CYP1B1.4
|
CYP1B1*4LR Bactosomes
|
CYP2A6
|
CYP2A6R Bactosomes
|
CYP2A13
|
CYP2A13LR Bactosomes
|
CYP2A13R Bactosomes
|
|
CYP2B6
|
CYP2B6BR Bactosomes
|
CYP2B6R Bactosomes
|
|
CYP2B6LR Bactosomes
|
|
CYP2C8
|
CYP2C8BR Bactosomes
|
CYP2C8BLR Bactosomes
|
|
CYP2C8R Bactosomes
|
|
CYP2C8LR Bactosomes
|
|
CYP2C9.1
|
CYP2C9BHR Bactosomes
|
CYP2C9BR Bactosomes
|
|
CYP2C9HR Bactosomes
|
|
CYP2C9R Bactosomes
|
|
CYP2C9.2
|
CYP2C9*2BR Bactosomes
|
CYP2C9*2R Bactosomes
|
|
CYP2C9.3
|
CYP2C9*3BR Bactosomes
|
CYP2C9*3R Bactosomes
|
|
CYP2C18
|
CYP2C18LR Bactosomes
|
CYP2C19
|
CYP2C19R Bactosomes
|
CYP2C19LR Bactosomes
|
|
CYP2D6.1
|
CYP2D6R Bactosomes
|
CYP2D6LR Bactosomes
|
|
CYP2D6.2
|
CYP2D6*2R Bactosomes
|
CYP2D6.10
|
CYP2D6*10R Bactosomes
|
CYP2D6.39
|
CYP2D6*39R Bactosomes
|
CYP2E1
|
CYP2E1BR Bactosomes
|
CYP2E1R Bactosomes
|
|
CYP2J2
|
CYP2J2LR Bactosomes
|
CYP3A4
|
CYP3A4BR Bactosomes
|
CYP3A4BLR Bactosomes
|
|
CYP3A4R Bactosomes
|
|
CYP3A4LR Bactosomes
|
|
CYP3A5
|
CYP3A5BR Bactosomes
|
CYP3A5BLR Bactosomes
|
|
CYP3A5R Bactosomes
|
|
CYP3A5LR Bactosomes
|
|
CYP4A11
|
CYP4A11BR Bactosomes
|
CYP4A11R Bactosomes
|
|
CYP4A11LR Bactosomes
|
|
CYP4F2
|
CYP4F2BLR Bactosomes
|
All the above products are supplied at 1 nmol CYP per vial.
|
|
2) CYPxxxR Easy CYP Bactosomes (human) 人细胞色素
|
|
Human CYP co-expressed with human NADPH-CYP reductase in E. coli
|
|
Enzyme
|
Product Description
|
CYP1A1
|
CYP1A1R EasyCYP Bactosomes
|
CYP1A1LR EasyCYP Bactosomes
|
|
CYP1A2
|
CYP1A2R EasyCYP Bactosomes
|
CYP1A2LR EasyCYP Bactosomes
|
|
CYP1B1.1
|
CYP1B1LR EasyCYP Bactosomes
|
CYP1B1.3
|
CYP1B1*3LR EasyCYP Bactosomes
|
CYP2A6
|
CYP2A6R EasyCYP Bactosomes
|
CYP2A13
|
CYP2A13R EasyCYP Bactosomes
|
CYP2A13LR EasyCYP Bactosomes
|
|
CYP2B6
|
CYP2B6BR EasyCYP Bactosomes
|
CYP2B6R EasyCYP Bactosomes
|
|
CYP2B6LR EasyCYP Bactosomes
|
|
CYP2C8
|
CYP2C8BR EasyCYP Bactosomes
|
CYP2C8BLR EasyCYP Bactosomes
|
|
CYP2C8R EasyCYP Bactosomes
|
|
CYP2C8LR EasyCYP Bactosomes
|
|
CYP2C9.1
|
CYP2C9BHR EasyCYP Bactosomes
|
CYP2C9BR EasyCYP Bactosomes
|
|
CYP2C9HR EasyCYP Bactosomes
|
|
CYP2C9R EasyCYP Bactosomes
|
|
CYP2C9.2
|
CYP2C9*2BR EasyCYP Bactosomes
|
CYP2C9*2R EasyCYP Bactosomes
|
|
CYP2C9.3
|
CYP2C9*3BR EasyCYP Bactosomes
|
CYP2C9*3R EasyCYP Bactosomes
|
|
CYP2C18
|
CYP2C18LR EasyCYP Bactosomes
|
CYP2C19
|
CYP2C19R EasyCYP Bactosomes
|
CYP2C19LR EasyCYP Bactosomes
|
|
CYP2D6.1
|
CYP2D6R EasyCYP Bactosomes
|
CYP2D6LR EasyCYP Bactosomes
|
|
CYP2D6.2
|
CYP2D6*2R EasyCYP Bactosomes
|
CYP2D6.10
|
CYP2D6*10R EasyCYP Bactosomes
|
CYP2D6.39
|
CYP2D6*39R EasyCYP Bactosomes
|
CYP2E1
|
CYP2E1BR EasyCYP Bactosomes
|
CYP2E1R EasyCYP Bactosomes
|
|
CYP2J2
|
CYP2J2LR EasyCYP Bactosomes
|
CYP3A4
|
CYP3A4BR EasyCYP Bactosomes
|
CYP3A4BLR EasyCYP Bactosomes
|
|
CYP3A4R EasyCYP Bactosomes
|
|
CYP3A4LR EasyCYP Bactosomes
|
|
CYP3A5
|
CYP3A5BR EasyCYP Bactosomes
|
CYP3A5BLR EasyCYP Bactosomes
|
|
CYP3A5R EasyCYP Bactosomes
|
|
CYP3A5LR EasyCYP Bactosomes
|
|
CYP4A11
|
CYP4A11BR EasyCYP Bactosomes
|
CYP4A11R EasyCYP Bactosomes
|
|
CYP4A11LR EasyCYP Bactosomes
|
|
CYP4F2
|
CYP4F2BLR EasyCYP Bactosomes
|
EasyCYP Bactosomes are prepared to a standard specification:
|
|
1 nmol CYP per ml; 10 mg total protein per ml; 0.5 nmol CYP per vial
|
|
3) Bactosome kits
|
|
Product Description
|
Contents
|
Low Reductase Bactosome Kit
|
1 vial of each of the following Bactosomes:
CYP1A2LR (CYP012); CYP2C9R (CYP006); CYP2C19LR (CYP028); CYP2D6LR (CYP013); CYP3A4LR (CYP010); Control (CYP003) |
High Reductase Bactosome Kit
|
1 vial of each of the following Bactosomes:
CYP1A2R (CYP001); CYP2C9HR (CYP019) CYP2C19R (CYP008); CYP2D6R (CYP007) CYP3A4R (CYP002); Control (CYP003) |
4) CYPxxxR Bactosomes (dog)
|
|
Dog CYP co-expressed with dog NADPH-CYP reductase in E. coli
|
|
Enzyme
|
Product Description
|
CYP1A1
|
Dog CYP1A1LR Bactosomes
|
CYP1A2
|
Dog CYP1A2LR Bactosomes
|
CYP2B11
|
Dog CYP2B11LR Bactosomes
|
CYP2C21
|
Dog CYP2C21LR Bactosomes
|
CYP2C41
|
Dog CYP2C41LR Bactosomes
|
CYP2D15
|
Dog CYP2D15LR Bactosomes
|
CYP3A12
|
Dog CYP3A12LR Bactosomes
|
CYP3A26
|
Dog CYP3A26LR Bactosomes
|
All the above products are supplied at 1 nmol CYP per vial.
|
|
5) Control preparations
|
|
Product Description
|
Size
|
Control Bactosomes
|
10 mg protein
|
Control EasyCYP Bactosomes
|
5 mg protein
|
Reductase Bactosomes
|
4 nmol reductase
|
Control cytosol
|
1 mg protein
|
Control EasyCYP Bactosomes are supplied at a standard protein concentration of 10 mg per ml.
|
|
Control cytosol is supplied at a standard protein concentration of 10 mg per ml.
|
|
6) Other enzymes
|
|
Product Description
|
Size
|
Human SULT1A1*1
|
1 mg cytosolic
|
Human SULT1A1*2
|
1 mg cytosolic
|
Human SULT1A2
|
1 mg cytosolic
|
Human SULT1A3
|
1 mg cytosolic
|
Human SULT1B1
|
1 mg cytosolic
|
Human SULT1C2
|
1 mg cytosolic
|
Human SULT1C4
|
1 mg cytosolic
|
Human SULT1E1
|
1 mg cytosolic
|
Human SULT2A1
|
1 mg cytosolic
|
Human GSTA1
|
1 mg cytosolic
|
Human GSTM1
|
1 mg cytosolic
|
Human aldehydeoxidase
|
250 μl cytosoli
|
Human aldehydedehydrogenase 1A1
|
1 mg cytosolic
|
Human carboxylesterase 1 (CES1)
|
1 mg membran
|
Human carboxylesterase 2 (CES2)
|
1 mg membran
|
Human UGT1A6 Bactosomes
|
5 mg membran
|
7) Antibodies (other than Nosan antibodies)
|
|
Product Description
|
Size
|
Pre-immune sheep serum
|
50 μl
|
Polyclonal sheep anti-rat UGT antiserum
|
50 μl
|
Polyclonal sheep anti-human SULT1A3 antiserum
|
50 μl
|
8) Chemicals | ||
Product Description | Size | |
4’-hydroxydiclofenac, > 98% | 0.1 mg | CYP2C9 metabolite of diclofenac |
5 mg | ||
6α-hydroxypaclitaxel, > 97% | 0.1 mg | CYP2C8 metabolite of paclitaxel |
5 mg | ||
[1-14C] lauric acid, > 98%, 49.4 mCi/mmol | 1.85 MBq(50 μCi) | Substrate for CYP2E1 and CYP4A11. |
[1-14C] 11-hydroxylauric acid, > 98%, 51.8 mCi/mmol | 1.85 MBq(50 μCi) | CYP2E1 metabolite of lauric acid (minor metabolite of CYP4A11). |
[1-14C] 12-hydroxylauric acid, > 98%, 50.8 mCi/mmol | 1.85 MBq | CYP4A11 metabolite of lauric acid. |
Tolbutamide, > 98% | 100 mg | Substrate for CYP2C. |
Hydroxytolbutamide, > 98% | 10 mg | CYP2C metabolite of tolbutamide. |
Carboxytolbutamide, > 98% | 10 mg | Metabolite of tolbutamide. |
Carboxytolbutamide methyl ester, > 98% | 10 mg | Derivative of carboxytolbutamide, a metabolite of tolbutamide. |
Tolbutamide kit (containsTolbutamide Hydroxytolbutamide Carboxytolbutamide Carboxytolbutamide methyl ester), > 98% | 100 mg of tolbutamide, 10 mg each of metabolites. | Tolbutamide Hydroxytolbutamide Carboxytolbutamide >Carboxytolbutamide methyl ester |
7-ethoxyresorufin, > 98% | 10 mg | Substrate for CYP1A1, CYP1A2 and CYP1B1. |
Resorufin, > 98% | 100 mg | CYP1A1, CYP1A2 and CYP1B1 metabolite of 7-ethoxyresorufin. |
7-benzyloxyquinoline (7BQ), > 98% | 10 mg | Substrate for CYP3A4. |
7-hydroxyquinoline (7HQ), > 98% | 10 mg | Metabolite of 7-BQ. |
[3-14C] 7-ethoxycoumarin, 46.0 mCi/mmol, > 99% | 1.85 MBq (50 μCi) | CYP substrate |
MAMC, > 98% | 10 mg | Substrate for CYP2D6. |
25 mg | ||
HAMC, > 98% | 10 mg | CYP2D6 metabolite of MAMC. |
7-methoxy-4-(trifluoromethyl)-coumarin (MFC), > 98% | 10 mg | Substrate for CYP2C9. |
25 mg | ||
7-benzyloxy-4-(trifluoromethyl)-coumarin (BFC), > 98% | 10 mg | Substrate for CYP3A4. |
25 mg | ||
7-hydroxy-4-(trifluoromethyl)-coumarin (HFC), > 98% | 10 mg | Metabolite of MFC and BFC. |
Omeprazole, > 98% | 1 g | Substrate of CYP2C19. |
3-O-methylfluorescein, > 98% | 10 mg | Substrate of CYP1A1 and CYP2C19. |
25 mg | ||
Tienilic acid, > 98% | 10 mg | Mechanism-based inhibitor of CYP2C9. |
25 mg | ||
Paclitaxel, > 98% | 25 mg | Substrate of CYP2C8. |
100 mg | ||
Ketoconazole, > 98% | 100 mg | CYP3A4 inhibitor. |
1 g | ||
Diclofenac, > 98% | 10 g | Substrate of CYP2C9 and CYP2C18. |
Amodiaquine dihydrochloride dihydrate, > 98% | 5 g | Substrate of CYP2C8. |
Desethylamodiaquine, > 98% | 10 mg | CYP2C8 metabolite of amodiaquine. |
25 mg | ||
Terfenadine, > 98% | 5 g | Substrate of CYP3A4 and CYP2J2 |
(-)-N-3-benzylphenobarbital, > 98% | 10 mg | Specific inhibitor of CYP2C19. |
25 mg | ||
Montelukast sodium | 10 mg | Inhibitor of CYP2C8. |
25 mg |
官网:www.cxbio.com | 微信服务号:iseebio | 微博:seebiobiotech |
商城:mall.seebio.cn | 微信订阅号:seebiotech | 泉养堂:www.canmedo.com |
下一篇:LUDOX 硅溶胶上一篇: 稳定同位素试剂,氘、氧十八
相关资讯
- α-乳白蛋白
- Seebio实验室仪器、耗材促销
- 西宝生物2019年端午放假及工作安排
- ACS Nano:突破!科学家利用来自尿液的生物标志物进行早期癌症筛查
- 酶稳定剂和蛋白保护剂
- Nature:细胞图谱揭示免疫系统抗击癌症新细节
- 中国蛋白质组学世界领先
- 饮食中反式脂肪酸使人健忘
- Cancer Res:科学家们在胰腺癌中发现了“抑癌细胞”
- Cell子刊:给CAR-T细胞标记上成像示踪剂,可在体内实时追踪CAR-T细胞
新进产品
同类文章排行
- 胆碱酯酶检测原料一览
- 猴痘病毒检测原料(涵盖诊断酶、抗原、抗体),西宝生物助力猴痘检测
- 西宝生物CHO细胞、HEK293细胞、 Vero细胞培养基产品
- 人和动物免疫球蛋白IgG全新上市
- 如何选择合适的表面活性剂?
- 尿液分析试纸检测原理及产品推荐
- 总胆红素/直接胆红素检测一站式解决方案
- 分子诊断用酶原料一站式服务尽在西宝生物
- 体外诊断中交联剂的用途与选择
- 优异的化妆品级水溶性β-1,3-葡聚糖